Abstract:AIM: It has been noticed that gastroenteritis or dysentery plays a role in pathogenesis of irritable bowel syndrome (IBS), and antibiotics can increase functional abdominal symptoms, both of which may be partly due to intestinal flora disorders. This study was to determine the change of gut flora of IBS, a cluster of abdominal symptoms. Because of the chronic course and frequent occurrence of the disease, IBS patients suffered much from it. So the quality of life (Qol) of IBS patients was also evaluated in this study.METHODS: Twenty-five Rome II criteria-positive IBS patients were recruited, and 25 age and gender-matched healthy volunteers were accepted as control. The fecal flora, including Lactobacillus, Bifidobacterium, Bacteroides, C. perfringens Enterobacteriacea and Enterococus, were analyzed quantitatively and qualitatively. We also calculated the ratio of Bifidobacterium to Enterobacteriaceae (B/E ratio) in both IBS patients and controls. In both groups, the data were further analyzed based on age difference, and comparisons were made between the younger and elder subgroups. We also evaluated the quality of life (QoL) of IBS patients and the control group using the Chinese version of SF-36 health questionnaire.RESULTS: In IBS patients, the number of fecal Bifidobacterium was significantly decreased and that of Enterobacteriaceae was significantly increased compared with that in healthy controls (both P<0.05). The mean microbial colonization resistance (CR) of the bowel in IBS patients was smaller than 1, making a significant difference compared with that in control which was more than 1 (P<0.01). There was no significant difference in gut flora between two subgroups. While in control, the elder subgroup presented more Enterobacteriacea than the younger one (P<0.05). Compared with the control group, IBS patients had significantly lower scores on all SF-36 scales, with the exception of physical functioning. However, there was no significant correlation between quality of life and enteric symptoms in IBS patients.CONCLUSION: There are intestinal flora disorders in IBS patients, which may be involved in triggering the IBS-like symptoms. IBS patients experience significant impairment in QoL, however, the impairment is not caused directly by enteric symptoms.

Gut microbiota and intestinal immunity—A crosstalk in irritable bowel syndrome

Intestinal Crosstalk between Bile Acids and Microbiota in irritable bowel syndrome

Gut Microbiota and Irritable Bowel Syndrome: Status and Prospect

Research progress of the relationship of gut microbiota, gut-brain axis with irritable bowel syndrome

Interplay of Intestinal Microbiota and Mucosal Immunity in Inflammatory Bowel Disease: a Relationship of Frenemies

Involvement Of Corticotropon-Relesing Factor And Receptors In Immune Cells In Irritable Bowel Syndrome

Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients

Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships

Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome

Analysis of the status of intestinal microecology and irritable bowel syndrome

Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome

The function of the gut microbiota–bile acid–TGR5 axis in diarrhea-predominant irritable bowel syndrome

Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome

Aggregation and Self-Assembly of Hydrophobins from Trichoderma Reesei: Low-Resolution Structural Models

Microbiome and Its Role in Irritable Bowel Syndrome

The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome

Mechanism of Involvement of Intestinal Microbiota in Pathogenesis of Irritable Bowel Syndrome

Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review

Advances in Study on Intestinal Flora Disorder and Irritable Bowel Syndrome

The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy

Distinctions Between Fecal and Intestinal Mucosal Microbiota in Subgroups of Irritable Bowel Syndrome